Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15749569 | 0.88 | EGFR (0.59) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749121 | 0.86 | EGFR (0.61) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749122 | 0.86 | EGFR (0.61) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749182 | 0.86 | EGFR (0.61) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749484 | 0.86 | EGFR (0.61) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749448 | 0.85 | EGFR (0.73) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749575 | 0.84 | EGFR (0.60) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749201 | 0.84 | EGFR (0.64) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749186 | 0.83 | EGFR (0.63) | EGFRCDK2JAK2KDRAURKB | |
| SCHEMBL15749541 | 0.83 | EGFR (0.65) | EGFRCDK2JAK2KDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | claimed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | claimed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | EGFR 1/4885CDK2 32/4885JAK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.